Last 12 months
Inside the activity.
0 purchase rows · 39 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 2 |
| Dec 2025 | 0 | 6 |
| Jan 2026 | 0 | 1 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 21 |
| Apr 2026 | 0 | 7 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 1 |
| Aug 2026 | 0 | 1 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 31, 2018 Filed Jun 4, 2018 20:10 UTC |
Clancy Paul JDirector
|
GrantStock option (right to buy) · Derivative | 5,700 | $0.00 Strike: $93.50 | $0.00 |
DisclosureSEC source: 0001209191-18-035022 · doc4.xml · derivative · entry 1 Clancy Paul J · CIK 0001409601 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,700 Underlying: Common stock · 5,700 shares Expires 2028-05-30 F1 · derivative.exercise_date: This option was granted on May 31, 2018. The shares underlying this option vest as to 100% of the underlying shares on May 31, 2019. Read SEC document |
| May 31, 2018 Filed Jun 4, 2018 20:15 UTC |
CLARK IAN TDirector
|
GrantRestricted stock units · Derivative | 1,400 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-035033 · doc4.xml · derivative · entry 2 CLARK IAN T · CIK 0001336504 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,400 Underlying: Common stock · 1,400 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F3 · derivative.exercise_date: The restricted stock units were granted on May 31, 2018. The shares underlying the stock units will vest in full on May 31, 2019. Vested shares will be delivered to the reporting person within three business days after such shares become vested. F3 · derivative.expiration_date: The restricted stock units were granted on May 31, 2018. The shares underlying the stock units will vest in full on May 31, 2019. Vested shares will be delivered to the reporting person within three business days after such shares become vested. Read SEC document |
| May 31, 2018 Filed Jun 4, 2018 20:15 UTC |
CLARK IAN TDirector
|
GrantStock option (right to buy) · Derivative | 5,700 | $0.00 Strike: $93.50 | $0.00 |
DisclosureSEC source: 0001209191-18-035033 · doc4.xml · derivative · entry 1 CLARK IAN T · CIK 0001336504 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,700 Underlying: Common stock · 5,700 shares Expires 2028-05-30 F1 · derivative.exercise_date: This option was granted on May 31, 2018. The shares underlying this option vest as to 100% of the underlying shares on May 31, 2019. Read SEC document |
| May 30, 2018 Filed Jun 1, 2018 20:08 UTC |
Schenkein David PDirector · Chief Executive Officer
|
Exercise / conversionStock option (right to buy) · Derivative | 23,471 | $0.00 Strike: $0.47 | $0.00 |
DisclosureSEC source: 0001209191-18-034644 · doc4.xml · derivative · entry 9 Schenkein David P · CIK 0001578200 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,892 Underlying: Common stock · 23,471 shares Expires 2021-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F8 · derivative.exercise_date: This option was granted on March 2, 2011. The shares underlying this option vested as to 25% of the shares on the date of grant and as to 25% of the shares upon the achievement of a performance milestone on July 19, 2013. The remaining 50% of the shares underlying the option vested in equal monthly installments through July 19, 2015. Read SEC document |
| May 30, 2018 Filed Jun 1, 2018 20:08 UTC |
Schenkein David PDirector · Chief Executive Officer
|
Exercise / conversionStock option (right to buy) · Derivative | 16,193 | $0.00 Strike: $0.30 | $0.00 |
DisclosureSEC source: 0001209191-18-034644 · doc4.xml · derivative · entry 8 Schenkein David P · CIK 0001578200 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common stock · 16,193 shares Expires 2019-08-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F7 · derivative.exercise_date: This option was granted on August 13, 2009. The shares underlying this option vested as to 50% upon the achievement of a performance milestone, as determined by the issuer's Board of Directors on June 3, 2010, and the remaining 50% of the underlying shares vested in equal monthly installments through June 3, 2013. Read SEC document |
| May 30, 2018 Filed Jun 1, 2018 20:08 UTC |
Schenkein David PDirector · Chief Executive Officer
|
Exercise / conversionStock option (right to buy) · Derivative | 5,962 | $0.00 Strike: $0.30 | $0.00 |
DisclosureSEC source: 0001209191-18-034644 · doc4.xml · derivative · entry 7 Schenkein David P · CIK 0001578200 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common stock · 5,962 shares Expires 2019-08-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F6 · derivative.exercise_date: This option was granted on August 13, 2009. The shares underlying this option vested as to 25% of the shares on August 1, 2010, and the remaining 75% vested in 36 equal monthly installments thereafter. Read SEC document |
| May 30, 2018 Filed Jun 1, 2018 20:08 UTC |
Schenkein David PDirector · Chief Executive Officer
|
SaleCommon stock | 45,626 | $90.07 | $4,109,533.82 |
DisclosureSEC source: 0001209191-18-034644 · doc4.xml · nonDerivative · entry 4 Schenkein David P · CIK 0001578200 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $90.00 to $90.63. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| May 30, 2018 Filed Jun 1, 2018 20:08 UTC |
Schenkein David PDirector · Chief Executive Officer
|
Exercise / conversionCommon stock | 23,471 | $0.47 | $10,972.69 |
DisclosureSEC source: 0001209191-18-034644 · doc4.xml · nonDerivative · entry 3 Schenkein David P · CIK 0001578200 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,626 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| May 30, 2018 Filed Jun 1, 2018 20:08 UTC |
Schenkein David PDirector · Chief Executive Officer
|
Exercise / conversionCommon stock | 16,193 | $0.30 | $4,898.38 |
DisclosureSEC source: 0001209191-18-034644 · doc4.xml · nonDerivative · entry 2 Schenkein David P · CIK 0001578200 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,155 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| May 30, 2018 Filed Jun 1, 2018 20:08 UTC |
Schenkein David PDirector · Chief Executive Officer
|
Exercise / conversionCommon stock | 5,962 | $0.30 | $1,803.51 |
DisclosureSEC source: 0001209191-18-034644 · doc4.xml · nonDerivative · entry 1 Schenkein David P · CIK 0001578200 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,962 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| May 23, 2018 Filed May 29, 2018 10:14 UTC |
Hoerter Steven L.Chief Commercial Officer
|
Exercise / conversionStock option (right to buy) · Derivative | 2,050 | $0.00 Strike: $39.76 | $0.00 |
DisclosureSEC source: 0001209191-18-033648 · doc4.xml · derivative · entry 3 Hoerter Steven L. · CIK 0001533451 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,800 Underlying: Common stock · 2,050 shares Expires 2026-02-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · derivative.exercise_date: This option was granted on February 16, 2016. The shares underlying this option vest as to 25% of the underlying shares on February 16, 2017, with the remaining 75% vesting in 36 equal monthly installments thereafter. Read SEC document |
| May 23, 2018 Filed May 29, 2018 10:14 UTC |
Hoerter Steven L.Chief Commercial Officer
|
SaleCommon stock | 2,050 | $85.76 | $175,808.00 |
DisclosureSEC source: 0001209191-18-033648 · doc4.xml · nonDerivative · entry 2 Hoerter Steven L. · CIK 0001533451 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| May 23, 2018 Filed May 29, 2018 10:14 UTC |
Hoerter Steven L.Chief Commercial Officer
|
Exercise / conversionCommon stock | 2,050 | $39.76 | $81,508.00 |
DisclosureSEC source: 0001209191-18-033648 · doc4.xml · nonDerivative · entry 1 Hoerter Steven L. · CIK 0001533451 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,050 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| May 23, 2018 Filed May 29, 2018 10:17 UTC |
Schenkein David PDirector · Chief Executive Officer
|
Exercise / conversionStock option (right to buy) · Derivative | 49,374 | $0.00 Strike: $0.30 | $0.00 |
DisclosureSEC source: 0001209191-18-033652 · doc4.xml · derivative · entry 7 Schenkein David P · CIK 0001578200 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,193 Underlying: Common stock · 49,374 shares Expires 2019-08-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F8 · derivative.exercise_date: This option was granted on August 13, 2009. The option vested as to 50% of the underlying shares upon the achievement of a performance milestone, as determined by the issuer's Board of Directors on June 3, 2010, and as to the remaining 50% of the underlying shares in equal monthly installments through June 3, 2013. Read SEC document |
| May 23, 2018 Filed May 29, 2018 10:17 UTC |
Schenkein David PDirector · Chief Executive Officer
|
SaleCommon stock | 299 | $92.03 | $27,516.97 |
DisclosureSEC source: 0001209191-18-033652 · doc4.xml · nonDerivative · entry 4 Schenkein David P · CIK 0001578200 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F5 · price: The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $92.01 to $92.04. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| May 23, 2018 Filed May 29, 2018 10:17 UTC |
Schenkein David PDirector · Chief Executive Officer
|
SaleCommon stock | 9,301 | $91.60 | $851,971.60 |
DisclosureSEC source: 0001209191-18-033652 · doc4.xml · nonDerivative · entry 3 Schenkein David P · CIK 0001578200 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 299 F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · price: The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $91.01 to $91.99. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| May 23, 2018 Filed May 29, 2018 10:17 UTC |
Schenkein David PDirector · Chief Executive Officer
|
SaleCommon stock | 39,774 | $90.11 | $3,584,035.14 |
DisclosureSEC source: 0001209191-18-033652 · doc4.xml · nonDerivative · entry 2 Schenkein David P · CIK 0001578200 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,600 F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $90.00 to $90.99. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| May 23, 2018 Filed May 29, 2018 10:17 UTC |
Schenkein David PDirector · Chief Executive Officer
|
Exercise / conversionCommon stock | 49,374 | $0.30 | $14,935.64 |
DisclosureSEC source: 0001209191-18-033652 · doc4.xml · nonDerivative · entry 1 Schenkein David P · CIK 0001578200 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,374 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| May 23, 2018 Filed May 29, 2018 10:11 UTC |
Biller ScottChief Scientific Officer
|
Exercise / conversionStock options (right to buy) · Derivative | 15,177 | $0.00 Strike: $31.64 | $0.00 |
DisclosureSEC source: 0001209191-18-033646 · doc4.xml · derivative · entry 3 Biller Scott · CIK 0001581956 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,862 Underlying: Common stock · 15,177 shares Expires 2024-03-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · derivative.exercise_date: This option was granted on March 5, 2014. The shares underlying this option vest as to 25% of the shares on March 5, 2015, with the remaining 75% vesting in 36 equal monthly installments thereafter. Read SEC document |
| May 23, 2018 Filed May 29, 2018 10:11 UTC |
Biller ScottChief Scientific Officer
|
SaleCommon stock | 15,177 | $90.00 | $1,365,930.00 |
DisclosureSEC source: 0001209191-18-033646 · doc4.xml · nonDerivative · entry 2 Biller Scott · CIK 0001581956 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,196 F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| May 23, 2018 Filed May 29, 2018 10:11 UTC |
Biller ScottChief Scientific Officer
|
Exercise / conversionCommon stock | 15,177 | $31.64 | $480,200.28 |
DisclosureSEC source: 0001209191-18-033646 · doc4.xml · nonDerivative · entry 1 Biller Scott · CIK 0001581956 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,373 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| May 23, 2018 Filed Aug 10, 2018 21:19 UTC Amendment |
Biller ScottChief Scientific Officer
|
Exercise / conversionStock option (right to buy) · Derivative | 15,177 | $0.00 Strike: $31.64 | $0.00 |
DisclosureSEC source: 0001209191-18-046266 · doc4a.xml · derivative · entry 1 Biller Scott · CIK 0001581956 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,862 Underlying: Common stock · 15,177 shares Expires 2024-03-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · shares: The original Form 4 stated that derivative securities were acquired as a result of the transaction, when in fact the transaction was a disposition of derivative securities. This Form 4 amendment is solely to correct the nature of the transaction. F3 · derivative.exercise_date: This option was granted on March 5, 2014. The shares underlying this option vest as to 25% of the shares on March 5, 2015, with the remaining 75% vesting in 36 equal monthly installments thereafter. Read SEC document |
| May 11, 2018 Filed May 15, 2018 20:13 UTC |
Bowden ChristopherChief Medical Officer
|
Exercise / conversionStock option (right to buy) · Derivative | 2,000 | $0.00 Strike: $35.16 | $0.00 |
DisclosureSEC source: 0001209191-18-030184 · doc4.xml · derivative · entry 4 Bowden Christopher · CIK 0001608601 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,000 Underlying: Common stock · 2,000 shares Expires 2024-05-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F5 · derivative.exercise_date: This option was granted on May 31, 2014. The shares underlying this option vest as to 25% of the underlying shares on May 13, 2015, with the remaining 75% vesting in 36 equal monthly installments thereafter. Read SEC document |
| May 11, 2018 Filed May 15, 2018 20:13 UTC |
Bowden ChristopherChief Medical Officer
|
SaleCommon stock | 1,160 | $85.14 | $98,762.40 |
DisclosureSEC source: 0001209191-18-030184 · doc4.xml · nonDerivative · entry 3 Bowden Christopher · CIK 0001608601 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 881 F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · price: The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $85.02 to $85.43. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| May 11, 2018 Filed May 15, 2018 20:13 UTC |
Bowden ChristopherChief Medical Officer
|
SaleCommon stock | 840 | $84.81 | $71,240.40 |
DisclosureSEC source: 0001209191-18-030184 · doc4.xml · nonDerivative · entry 2 Bowden Christopher · CIK 0001608601 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,041 F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $84.02 to $85.00. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| May 11, 2018 Filed May 15, 2018 20:13 UTC |
Bowden ChristopherChief Medical Officer
|
Exercise / conversionCommon stock | 2,000 | $35.16 | $70,320.00 |
DisclosureSEC source: 0001209191-18-030184 · doc4.xml · nonDerivative · entry 1 Bowden Christopher · CIK 0001608601 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,881 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| May 08, 2018 Filed May 10, 2018 20:00 UTC |
Bowden ChristopherChief Medical Officer
|
Exercise / conversionStock option (right to buy) · Derivative | 2,000 | $0.00 Strike: $35.16 | $0.00 |
DisclosureSEC source: 0001209191-18-029223 · doc4.xml · derivative · entry 3 Bowden Christopher · CIK 0001608601 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,000 Underlying: Common stock · 2,000 shares Expires 2024-05-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · derivative.exercise_date: This option was granted on May 31, 2014. The shares underlying this option vest as to 25% of the underlying shares on May 13, 2015, with the remaining 75% vesting in 36 equal monthly installments thereafter. Read SEC document |
| May 08, 2018 Filed May 10, 2018 20:00 UTC |
Bowden ChristopherChief Medical Officer
|
SaleCommon stock | 2,000 | $81.38 | $162,760.00 |
DisclosureSEC source: 0001209191-18-029223 · doc4.xml · nonDerivative · entry 2 Bowden Christopher · CIK 0001608601 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 881 F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $80.75 to $81.65. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| May 08, 2018 Filed May 10, 2018 20:00 UTC |
Bowden ChristopherChief Medical Officer
|
Exercise / conversionCommon stock | 2,000 | $35.16 | $70,320.00 |
DisclosureSEC source: 0001209191-18-029223 · doc4.xml · nonDerivative · entry 1 Bowden Christopher · CIK 0001608601 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,881 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| May 07, 2018 Filed May 8, 2018 20:08 UTC |
Biller ScottChief Scientific Officer
|
Exercise / conversionStock options (right to buy) · Derivative | 3,000 | $0.00 Strike: $9.05 | $0.00 |
DisclosureSEC source: 0001209191-18-028538 · doc4.xml · derivative · entry 3 Biller Scott · CIK 0001581956 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,154 Underlying: Common stock · 3,000 shares Expires 2023-04-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · derivative.exercise_date: This option was originally granted on April 30, 2013 for the purchase of 68,181 shares of common stock. The option vests as to 50% of the underlying shares upon the achievement of a performance milestone, and as to the remaining 50% of upon the achievement of a second performance milestone. The Company's board of directors determined that the first performance milestone was achieved on December 3, 2015, resulting in the vesting of this option as to 34,091 shares. On January 26, 2017, the Company's board of directors determined that the second performance milestone was achieved, resulting in the vesting of this option as to the remaining 34,090 shares. Read SEC document |
| May 07, 2018 Filed May 8, 2018 20:08 UTC |
Biller ScottChief Scientific Officer
|
SaleCommon stock | 3,000 | $81.81 | $245,430.00 |
DisclosureSEC source: 0001209191-18-028538 · doc4.xml · nonDerivative · entry 2 Biller Scott · CIK 0001581956 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,196 F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $81.30 to $82.28. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| May 07, 2018 Filed May 8, 2018 20:08 UTC |
Biller ScottChief Scientific Officer
|
Exercise / conversionCommon stock | 3,000 | $9.05 | $27,150.00 |
DisclosureSEC source: 0001209191-18-028538 · doc4.xml · nonDerivative · entry 1 Biller Scott · CIK 0001581956 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,196 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| May 07, 2018 Filed Aug 10, 2018 21:18 UTC Amendment |
Biller ScottChief Scientific Officer
|
Exercise / conversionStock option (right to buy) · Derivative | 3,000 | $0.00 Strike: $9.05 | $0.00 |
DisclosureSEC source: 0001209191-18-046265 · doc4a.xml · derivative · entry 1 Biller Scott · CIK 0001581956 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,154 Underlying: Common stock · 3,000 shares Expires 2023-04-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · shares: The original Form 4 stated that derivative securities were acquired as a result of the transaction, when in fact the transaction was a disposition of derivative securities. This Form 4 amendment is solely to correct the nature of the transaction. F3 · derivative.exercise_date: This option was originally granted on April 30, 2013 for the purchase of 68,181 shares of common stock. The option vests as to 50% of the underlying shares upon the achievement of a performance milestone, and as to the remaining 50% of upon the achievement of a second performance milestone. The Company's board of directors determined that the first performance milestone was achieved on December 3, 2015, resulting in the vesting of this option as to 34,091 shares. On January 26, 2017, the Company's board of directors determined that the second performance milestone was achieved, resulting in the vesting of this option as to the remaining 34,090 shares. Read SEC document |
| May 01, 2018 Filed May 3, 2018 20:07 UTC |
Schenkein David PDirector · Chief Executive Officer
|
Exercise / conversionStock option (right to buy) · Derivative | 13,000 | $0.00 Strike: $0.30 | $0.00 |
DisclosureSEC source: 0001209191-18-027582 · doc4.xml · derivative · entry 7 Schenkein David P · CIK 0001578200 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,567 Underlying: Common stock · 13,000 shares Expires 2019-08-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F7 · derivative.exercise_date: This option was granted on August 13, 2009. The option vested as to 50% of the underlying shares upon the achievement of a performance milestone, as determined by the issuer's Board of Directors on June 3, 2010, and as to the remaining 50% of the underlying shares in equal monthly installments through June 3, 2013. Read SEC document |
| May 01, 2018 Filed May 3, 2018 20:07 UTC |
Schenkein David PDirector · Chief Executive Officer
|
SaleCommon stock | 100 | $84.35 | $8,435.00 |
DisclosureSEC source: 0001209191-18-027582 · doc4.xml · nonDerivative · entry 4 Schenkein David P · CIK 0001578200 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| May 01, 2018 Filed May 3, 2018 20:07 UTC |
Schenkein David PDirector · Chief Executive Officer
|
SaleCommon stock | 2,814 | $83.56 | $235,137.84 |
DisclosureSEC source: 0001209191-18-027582 · doc4.xml · nonDerivative · entry 3 Schenkein David P · CIK 0001578200 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100 F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · price: The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $83.29 to $84.20. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| May 01, 2018 Filed May 3, 2018 20:07 UTC |
Schenkein David PDirector · Chief Executive Officer
|
SaleCommon stock | 10,086 | $82.88 | $835,927.68 |
DisclosureSEC source: 0001209191-18-027582 · doc4.xml · nonDerivative · entry 2 Schenkein David P · CIK 0001578200 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,914 F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $82.29 to $83.28. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| May 01, 2018 Filed May 3, 2018 20:07 UTC |
Schenkein David PDirector · Chief Executive Officer
|
Exercise / conversionCommon stock | 13,000 | $0.30 | $3,932.50 |
DisclosureSEC source: 0001209191-18-027582 · doc4.xml · nonDerivative · entry 1 Schenkein David P · CIK 0001578200 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| April 23, 2018 Filed Apr 25, 2018 20:12 UTC |
Hoerter Steven L.Chief Commercial Officer
|
Exercise / conversionStock option (right to buy) · Derivative | 2,050 | $0.00 Strike: $39.76 | $0.00 |
DisclosureSEC source: 0001209191-18-026071 · doc4.xml · derivative · entry 3 Hoerter Steven L. · CIK 0001533451 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,850 Underlying: Common stock · 2,050 shares Expires 2026-02-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · derivative.exercise_date: This option was granted on February 16, 2016. The shares underlying this option vest as to 25% of the underlying shares on February 16, 2017, with the remaining 75% vesting in 36 equal monthly installments thereafter. Read SEC document |
| April 23, 2018 Filed Apr 25, 2018 20:12 UTC |
Hoerter Steven L.Chief Commercial Officer
|
SaleCommon stock | 2,050 | $85.95 | $176,197.50 |
DisclosureSEC source: 0001209191-18-026071 · doc4.xml · nonDerivative · entry 2 Hoerter Steven L. · CIK 0001533451 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| April 23, 2018 Filed Apr 25, 2018 20:12 UTC |
Hoerter Steven L.Chief Commercial Officer
|
Exercise / conversionCommon stock | 2,050 | $39.76 | $81,508.00 |
DisclosureSEC source: 0001209191-18-026071 · doc4.xml · nonDerivative · entry 1 Hoerter Steven L. · CIK 0001533451 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,050 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| April 12, 2018 Filed Apr 16, 2018 20:01 UTC |
Bowden ChristopherChief Medical Officer
|
Exercise / conversionStock option (right to buy) · Derivative | 2,000 | $0.00 Strike: $35.16 | $0.00 |
DisclosureSEC source: 0001209191-18-024967 · doc4.xml · derivative · entry 4 Bowden Christopher · CIK 0001608601 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,000 Underlying: Common stock · 2,000 shares Expires 2024-05-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F5 · derivative.exercise_date: This option was granted on May 31, 2014. The shares underlying this option vest as to 25% of the underlying shares on May 13, 2015, with the remaining 75% vesting in 36 equal monthly installments thereafter. Read SEC document |
| April 12, 2018 Filed Apr 16, 2018 20:01 UTC |
Bowden ChristopherChief Medical Officer
|
SaleCommon stock | 700 | $85.68 | $59,976.00 |
DisclosureSEC source: 0001209191-18-024967 · doc4.xml · nonDerivative · entry 3 Bowden Christopher · CIK 0001608601 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 881 F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · price: The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $85.22 to $85.95. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| April 12, 2018 Filed Apr 16, 2018 20:01 UTC |
Bowden ChristopherChief Medical Officer
|
SaleCommon stock | 1,300 | $84.78 | $110,214.00 |
DisclosureSEC source: 0001209191-18-024967 · doc4.xml · nonDerivative · entry 2 Bowden Christopher · CIK 0001608601 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,581 F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $84.21 to $85.16. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| April 12, 2018 Filed Apr 16, 2018 20:01 UTC |
Bowden ChristopherChief Medical Officer
|
Exercise / conversionCommon stock | 2,000 | $35.16 | $70,320.00 |
DisclosureSEC source: 0001209191-18-024967 · doc4.xml · nonDerivative · entry 1 Bowden Christopher · CIK 0001608601 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,881 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| April 05, 2018 Filed Apr 9, 2018 20:09 UTC |
Biller ScottChief Scientific Officer
|
Exercise / conversionStock options (right to buy) · Derivative | 3,000 | $0.00 Strike: $9.05 | $0.00 |
DisclosureSEC source: 0001209191-18-024317 · doc4.xml · derivative · entry 6 Biller Scott · CIK 0001581956 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,154 Underlying: Common stock · 3,000 shares Expires 2023-04-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F7 · derivative.exercise_date: This option was originally granted on April 30, 2013 for the purchase of 68,181 shares of common stock. The option vests as to 50% of the underlying shares upon the achievement of a performance milestone, and as to the remaining 50% of upon the achievement of a second performance milestone. The Company's board of directors determined that the first performance milestone was achieved on December 3, 2015, resulting in the vesting of this option as to 34,091 shares. On January 26, 2017, the Company's board of directors determined that the second performance milestone was achieved, resulting in the vesting of this option as to the remaining 34,090 shares. Read SEC document |
| April 05, 2018 Filed Apr 9, 2018 20:09 UTC |
Biller ScottChief Scientific Officer
|
SaleCommon stock | 500 | $77.17 | $38,585.00 |
DisclosureSEC source: 0001209191-18-024317 · doc4.xml · nonDerivative · entry 5 Biller Scott · CIK 0001581956 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,196 F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F6 · price: The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $76.70 to $77.64. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| April 05, 2018 Filed Apr 9, 2018 20:09 UTC |
Biller ScottChief Scientific Officer
|
SaleCommon stock | 800 | $76.17 | $60,936.00 |
DisclosureSEC source: 0001209191-18-024317 · doc4.xml · nonDerivative · entry 4 Biller Scott · CIK 0001581956 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,696 F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F5 · price: The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $75.69 to $76.64. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| April 05, 2018 Filed Apr 9, 2018 20:09 UTC |
Biller ScottChief Scientific Officer
|
SaleCommon stock | 400 | $75.04 | $30,016.00 |
DisclosureSEC source: 0001209191-18-024317 · doc4.xml · nonDerivative · entry 3 Biller Scott · CIK 0001581956 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,496 F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · price: The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $74.68 to $75.38. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| April 05, 2018 Filed Apr 9, 2018 20:09 UTC |
Biller ScottChief Scientific Officer
|
SaleCommon stock | 1,300 | $73.90 | $96,070.00 |
DisclosureSEC source: 0001209191-18-024317 · doc4.xml · nonDerivative · entry 2 Biller Scott · CIK 0001581956 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,896 F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $73.41 to $74.39. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.